Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422452 | 0.94 | PTGDR2 (0.52) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL2539312 | 0.87 | PTGDR2 (0.47) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL2541818 | 0.85 | SMN1; SMN2 (0.44) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL1783342 | 0.83 | PTGDR2 (0.51) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL1466409 | 0.81 | PTGDR2 (0.56) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL5320658 | 0.81 | SMN1; SMN2 (0.41) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL1467731 | 0.79 | PTGDR2 (0.52) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL3719025 | 0.78 | PTGDR2 (0.51) | PTGDR2CYP2C9PTGDRAKR1B1 | |
| SCHEMBL1603176 | 0.77 | PTGDR2 (0.56) | PTGDR2CYP2C9PTGDR | |
| SCHEMBL1467977 | 0.77 | PTGDR2 (0.62) | PTGDR2CYP2C9PTGDRAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044088-B2 | 1-acetic acid-indole derivatives with PGD2 antagonist activity | OXAGEN LIMITED (GB) | 2011-10-25 | — | — | US | claimed |
| US-20100330077-A1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2010-12-30 | — | — | US | claimed |
| EP-1856045-B1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LTD (GB) | 2009-09-09 | — | — | EP | claimed |
| EP-1856045-A1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | Oxagen Limited (GB) | 2007-11-21 | — | — | EP | claimed |
| WO-2006095183-A1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2006-09-14 | — | — | WO | claimed |
| US-8044088-B2 | 1-acetic acid-indole derivatives with PGD2 antagonist activity | OXAGEN LIMITED (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20100330077-A1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2010-12-30 | — | — | US | disclosed |
| EP-1856045-B1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | OXAGEN LTD (GB) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330077-A1 | 1-ACETIC ACID-INDOLE DERIVATIVES WITH PGD2 ANTAGONIST ACTIVITY | PTGDR, PTGDR2, PTGER1 | PTGDR2 2/4885CYP2C9 867/4885PTGDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.